Trending...
- Willie D Joins Saitama LLC Crypto And NFT Content Creation Team In Multi-million Dollar Deal
- 14:15 ET Pittsburgh International Airport Breaks Ground on $1.4 Billion New Tech-Forward Terminal, First Airport to be Built from the Ground Up Post-Pandemic
- Pennsylvania: Governor Wolf Announces Funding for Affordable Rental Housing
WEST CHESTER, Pa., Sept. 16, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce the additional close of funds totaling >$5.2M of Series A financing, which includes conversion of all existing convertible notes.
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
More on The PennZone
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
More on The PennZone
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
More on The PennZone
- Pennsylvania: Gov. Wolf Highlights Grant Program to Promote Community Outreach on COVID-19 Vaccine
- Option trading activity for Affirm stock is unusually high
- IntegraCare to manage senior living communities in Exton, Glen Mills
- The End to Gerrymandering in Michigan?
- Pennsylvania: Wolf Administration Funds $2 Million in Research to Grow PA Agriculture Industry
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
More on The PennZone
- $SNE Token Sale Goes Live: Here's What You Need to Know About the Upcoming StrongNode.io IDO Launch
- Pennsylvania: Gov. Wolf Announces Funding for Somerset County Navy Supplier to Train Apprentices for Manufacturing Jobs
- Pennsylvania: Wolf Administration to Host Vaccine Clinic in Lancaster County
- Activision and Electronic Arts Marketing Executive Kimberly Salzer Steps in as VP for Global Marketing of StrongNode.io
- Pennsylvania: Gov. Wolf Announces Expansion of Federal Disaster Declaration Assistance Following Damage Caused by Ida Remnants
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Filed Under: Business
0 Comments
Latest on The PennZone
- CNXT Digital Brings Student Life and Family Engagement Together in One Integrated Solution K-12
- Gov. Wolf: 70 Percent of Pennsylvanians Aged 18 and Older are Fully Vaccinated
- AUSA 2021: CP North America Showcases Combat Proven Solutions for Military, Industrial and Commercial Applications
- Haunted Attractions Go from 5-Star Reviews to Legendary Status in the U.S
- Nutrition Industry Executive Awarded the NIE 2021 Award for the Condition Specific Category to Stratum Nutrition's Ingredient LBiome™
- Dental Implant Services in Springfield, PA Available from DICE Dental
- Pennsylvania: First Lady Wolf, Corrections Acting Sec. George Little, and Criminal Justice Reform Advocates Highlight Unique Needs of Women in Reentry
- Save Time and Money with Texpak's New PCA Tagging System
- TowerData and FreshAddress Merge to Form Premier Email Data Technology Company
- 11:20 ET [PRODUCT LAUNCH] - EPIQ QMS by Caliber - Enterprise Platform for Integrated Quality
- Picard Investment Group Announces Distribution Licensing Agreement of New Organic Medicinal Product for Shingles and Herpes Simplex Viruses
- "LA eats JAPAN" Comes to Little Tokyo in Los Angeles with Street Food and Live Performances
- Dave Reit (aka "DR") Releases New Single "Hiding" Featuring Futuristic
- Oklahoma The Newest Meet Now App has Arrived "Sooner" than Expected!
- "Follows and Likes Is This All That I'm Worth?" A Multicultural Book for Teens and YA On How to Understand True Success in the Age of Social Media
- StrongNode.io Welcomes Fintech and Digital Payments Expert Eliza Hayashi as its New Advisor ahead of its $SNE Token Launch
- 16:51 ET "QVC Presents 28th Annual FFANY Shoes on Sale" Fundraiser on Track to Top $60 Million After Campaign Wraps on December 31
- IaaS Technology Company StrongNode.io Announces SGG World's Natalia Sokolova as New Advisor for Investor Relations
- DG Meditech Opens Doors to North American Operations With Appointment of New Chief for Americas
- Willie D Joins Saitama LLC Crypto And NFT Content Creation Team In Multi-million Dollar Deal